These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31823667)

  • 1. Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients.
    Peng J; Wang Z; Li Y; Lv D; Zhao X; Gao J; Teng H
    Hum Exp Toxicol; 2020 Apr; 39(4):393-401. PubMed ID: 31823667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 3. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
    Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
    J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
    Meinardi MT; van Veldhuisen DJ; Gietema JA; Dolsma WV; Boomsma F; van den Berg MP; Volkers C; Haaksma J; de Vries EG; Sleijfer DT; van der Graaf WT
    J Clin Oncol; 2001 May; 19(10):2746-53. PubMed ID: 11352968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin.
    Okamoto T; Ogata J; Minami K
    Anesth Analg; 2003 Jul; 97(1):19-20, table of contents. PubMed ID: 12818936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
    Jensen BV; Skovsgaard T; Nielsen SL
    Ann Oncol; 2002 May; 13(5):699-709. PubMed ID: 12075737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients.
    Bi X; Deng Y; Zeng F; Zhu Y; Wu Y; Zhao C; Li C
    J Huazhong Univ Sci Technolog Med Sci; 2009 Jun; 29(3):391-4. PubMed ID: 19513629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
    Zhang H; Shen WS; Gao CH; Deng LC; Shen D
    Drugs R D; 2012 Jun; 12(2):101-6. PubMed ID: 22770377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.
    Singh P; Shah DA; Jouni M; Cejas RB; Crossman DK; Magdy T; Qiu S; Wang X; Zhou L; Sharafeldin N; Hageman L; McKenna DE; Armenian SH; Balis FM; Hawkins DS; Keller FG; Hudson MM; Neglia JP; Ritchey AK; Ginsberg JP; Landier W; Bhatia R; Burridge PW; Bhatia S
    J Am Heart Assoc; 2023 Oct; 12(19):e029954. PubMed ID: 37750583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
    Michelotti A; Venturini M; Tibaldi C; Bengala C; Gallo L; Carnino F; Del Mastro L; Lionetto R; Montanaro E; Rosso R; Conte P
    Breast Cancer Res Treat; 2000 Jan; 59(2):133-9. PubMed ID: 10817348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.